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Hereditary C1 esterase deficiency in a Zulu kindred
E Moran, G S Isaacs, B Naidoo, D J Pudifin
To the Editor: Hereditary angio-oedema is a rare genetic 
disorder characterised by recurrent episodes of potentially 
life-threatening angio-oedema. Despite the apparent absence 
of variation in incidence among ethnic groups, this is the first 
reported series in a sub-Saharan African family, and it is likely 
that the disease remains largely undiagnosed in southern 
Africa. Although cost and availability limit the use of certain 
treatments which are available in resource-rich health systems, 
early diagnosis allows patient education and the initiation of 
less costly, more widely available prophylactic medications 
that are life-saving in individuals at risk of severe attacks. The 
diagnosis should be considered in the differential diagnosis of 
those presenting with apparent allergies and drug reactions.
Case description and diagnosis
Several family members who had all experienced repeated 
episodes of angio-oedema were seen at Hlabisa District 
Hospital and King Edward VIII Hospital. The first (NM1), a 16-
year-old girl, presented twice to Hlabisa with acute onset facial 
swelling and respiratory difficulty. The swelling of her face and 
tongue was unresponsive to intramuscular adrenaline and 
intravenous steroids. On both occasions, she developed stridor 
and required endotracheal intubations when severe laryngeal 
oedema was noted. The oedema settled spontaneously over 2 - 
3 days. She had had similar, milder episodes about twice a year 
over the previous 10 years, and other family members had 
similar episodes.
The second patient (NM2), a 14-year-old cousin of NM1, was 
well at the time of assessment. She gave a history of attacks 
of swelling of the lips, face and neck which had started at a 
young age and resolved spontaneously. She said her brother 
experienced similar attacks and that her father had died as a 
result of a severe episode.
NM3, the 12-year-old brother of NM1, presented to Hlabisa 
with spontaneous facial swelling which subsided after the 
administration of freeze-dried plasma. Similar episodes had 
occurred about twice a year over the previous 5 years.
There were no identifiable precipitating factors for the angio-
oedema in the 3 patients, and they were otherwise well and 
physically normal. Since circumstances strongly suggested the 
diagnosis of familial angio-oedema, complement function was 
investigated, which confirmed a low C4 level and deficiency of 
C1 esterase in all 3.
Three other family members (SS, DM and SM) were seen 
only once as outpatients, and limited data are available (Table 
I). SS and DM had experienced mild cutaneous episodes. 
SM, the 34-year-old aunt of NM1, had experienced recurrent 
episodes of abdominal pain, sometimes associated with 
facial swelling. A laparotomy and cholecystectomy had 
been performed following ultrasound demonstration of a 
single gallstone, but episodes of pain persisted. There were 
no abnormal signs apart from mild generalised abdominal 
tenderness during the attacks, which always settled 
spontaneously over a few days. Full blood count, serum urea, 
electrolytes and liver function were normal when the patient 
was seen.
These findings indicate that this kindred of African/Zulu 
descent harbours one of the mutations giving rise to deficiency 
of C1 esterase, and this is believed to be the first report of this 
abnormality in this ethnic group. (The literature search was 
performed using Pubmed, and the terms Africa and African and 
Zulu in combination with each of C1 esterase inhibitor, hereditary 
angio-oedema and hereditary angioedema. Although cases have 
been identified in North Africa and North America among 
individuals described as ‘African-American’, there were no 
cases reported among those of confirmed sole sub-Saharan 
African descent.)
Pathogenesis and clinical features of 
hereditary angio-oedema
Hereditary angio-oedema (HA) is a rare autosomal dominant 
disorder characterised by recurrent episodes of angio-oedema 
without urticaria or pruritus. Incidence is estimated at around 
1/50 000, with no described variation between ethnic groups. 
Most commonly affecting the skin and tissues of the upper 
airways, attacks are self-limited but laryngeal involvement 
can lead to airway obstruction and death. It is a consequence 
of either a deficiency (type 1 – 85% of affected families) or 
a dysfunction (type 2) of C1 inhibitor (C1-INH) – a protein 
that prevents complement activation by both the classic route 
and the mannan-binding pathway.1 C1-INH is additionally 
involved in the regulation of the coagulation and fibrinolytic 
and kinin-generating pathways and, although the specific 
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mediator responsible for the generation of angio-oedema 
has not been identified, increasing evidence implicates the 
vasodilatory protein bradykinin. The gene for C1-INH is located 
on chromosome 11, and well over 100 mutations have been 
identified in HA patients, most of which are single base-pair 
mutations. Around a quarter of cases are due to new mutations. 
The severity of clinical attacks varies even within the same 
family possessing the same mutation; the factors influencing 
severity are not known. Some individuals found to have C1-INH 
deficiency through family screening never develop attacks.1
Although attacks of angio-oedema may occur spontaneously 
with no obvious precipitant, some patients may be able to 
identify specific triggers such as dental work, mild trauma, 
stress, excitement, certain foods, oestrogen, menstruation, and 
angiotensin-converting enzyme (ACE) inhibitors. A prodrome 
of mood or skin changes may precede an episode. Attacks may 
be cutaneous, abdominal or laryngeal1 and, although often 
affecting a single site, may affect two or more sites (e.g. facial 
swelling progressing to laryngeal oedema, as in NM1). Half of 
affected individuals experience all three forms of attack in their 
lifetimes; 40% experience their first attack before age 5 years, 
and 75% by age 15 years. Repeated attacks are uncommon 
before adolescence, after which attack frequency increases.
Cutaneous attacks tend to affect the hands, feet, face and 
genitals, with swelling lasting 2 - 4 days. Abdominal attacks 
cause pain, nausea, vomiting and diarrhoea (because of bowel 
wall oedema). Most patients experience an abdominal attack 
at some point in their lives that lasts around 4 days, with 
symptoms peaking on day 2. Resemblance to the acute surgical 
abdomen leads to unnecessary surgery in around a third of 
patients with undiagnosed HA (as in SM). Laryngeal attacks 
occur in half of all patients at some point in their lives, and are 
less common after the age of 45 years. They can occur in the 
absence of swelling of the upper airway and lips. It usually takes 
a few hours to progress from first symptom to potential airway 
obstruction, but obstruction can occur within half an hour of first 
symptom.
Diagnosis and treatment
Initial screening is by measuring C4 and C1 inhibitor levels 
in a patient with a suggestive personal or family history (e.g. 
repeated episodes of facial swelling or abdominal pain or an 
affected relative). Both levels are likely to be reduced in an 
affected individual; 90% of HA patients have low C4 levels 
even when asymptomatic, and most have low C4 levels during 
attacks. A normal C4 in an asymptomatic patient does not 
exclude HA.2 Confirmation is by full complement studies, 
ideally performed on two samples taken at least 4 weeks apart. 
Patients should be off all therapy for HA for at least 3 weeks 
before testing. If C1q is normal and C4 and C1-INH levels are 
low, the diagnosis may be HA type 1 (deficient C1-INH). If 
C1q is normal and C4 is low, but C1-INH levels are normal 
or raised, the diagnosis may be HA type 2 (dysfunctional C1-
INH) and functional assays of C1-INH should be performed. If 
function is less than 30% of normal, the diagnosis is probably 
HA type 2. Genetic testing is not required to confirm the 
diagnosis in adults. In children <1 year of age, complement 
levels are difficult to interpret, and the diagnosis should be 
confirmed by either repeating the assays when the child is 
older or by genetic testing.
If a patient with possible HA has no family history or is 
older than 40 years at first presentation, a rare form of acquired 
C1-INH deficiency is possible. The diagnosis is suggested by 
low C1q and C4 levels. Such patients should be screened for 
malignancy, as 85% are found to have lymphoproliferative 
disorders. Genetic studies may be required. In addition 
to acquired C1-INH deficiency, the differential diagnosis 
for HA includes autoimmune disease (e.g. systemic lupus 
erythematosus, which may cause an isolated low C4), allergy, 
anaphylaxis, idiopathic or drug-induced angio-oedema, and 
parasitic infection.
Treatment of acute attacks
Swift emergency management of laryngeal attacks can be 
life saving; airway management is paramount, and severely 
affected individuals may require urgent intubation or 
cricothyroidotomy. Antihistamines, steroids and adrenaline are 
not effective but are often given, particularly if the diagnosis 
is in doubt or not confirmed. The most effective medical 
treatment for acute episodes of HA is intravenous C1 esterase 
inhibitor protein,3 which is manufactured from pooled human 
plasma, and where available is considered the treatment of 
Table I. Clinical and laboratory data
                      C3                 C4                 C1 esterase
Patient  Relationship to NM1     Clinical pattern                (0.86 - 1.84 g/l) (0.2 - 0.58 g/l) (0.12 - 0.25 g/l)
NM1  Index                C, L                1.36  0.05   0.05
NM2  14-year-old female cousin              C                 1.45  0.04   0.07
NM3  12-year-old brother               C                 Not available Not available  0.05
DM  54-year-old father               C                 Not available 0.17                  Not available
SS  15-year-old male cousin              C                 Not available 0.03                  Not available
SM  34-year-old aunt               A                 Not available Not available   Not available
C = cutaneous attacks; L = laryngeal attacks; A = abdominal attacks.
Normal ranges for laboratory values in brackets.
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choice for laryngeal and severe abdominal attacks. However, 
it is expensive and not widely used outside Europe, Canada 
and certain other countries. Fresh-frozen plasma contains 
several complement proteins and is considered first-line 
therapy where C1 esterase inhibitor protein is not available.4 
These therapies carry the risk of transmission of blood-borne 
viruses, and trials of both recombinant and treated C1 esterase 
inhibitor preparations are under way.5 Tranexamic acid is used 
in the treatment of laryngeal, abdominal and severe cutaneous 
attacks.1,6 It is most effective if given early in the course of 
symptoms; its mechanism of action is unclear. Symptomatic 
therapy for pain, vomiting and abdominal cramps should also 
be given.
Prophylaxis of attacks
Synthetic androgens such as danazol are effective in short- and 
long-term prophylaxis by increasing hepatic production of C1-
INH, but have significant side-effects.7 Long-term prophylaxis 
should be considered if patients have experienced laryngeal 
attacks (particularly if C1-INH protein replacement is not 
available) or more than one severe attack a month. To avoid 
side-effects, the dose should be titrated to find the lowest 
effective dose. Short-term prophylaxis should be given to 
patients undergoing elective surgery and may also be indicated 
before dental work. Although short-term treatment with 
synthetic androgens is usually well tolerated by children and 
adults, long-term treatment can lead to menstrual irregularities 
in premenopausal women, and weight gain in men and 
women. Long-term use should be avoided in children and 
pregnant women, who should instead receive tranexamic 
acid which, although less effective, can be used for prolonged 
periods. C1 esterase inhibitor protein can be used for long-term 
prophylaxis in selected patients.3
Non-medical measures important in the long-term 
management of HA include education and avoidance of any 
identified trigger. Patients should be counselled to seek early 
hospital care, particularly if they have a record of laryngeal 
attacks, and be provided with an emergency treatment plan to 
show to hospital emergency departments to facilitate prompt 
effective therapy.
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